Abstract Number: 1671 • 2018 ACR/ARHP Annual Meeting
Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
Background/Purpose: The Physician Global Assessment (PGA) is a frequently-used outcome measure in Systemic Lupus Erythematosus (SLE). The PGA is intended to encapsulate the physician’s judgement…Abstract Number: 1672 • 2018 ACR/ARHP Annual Meeting
Poor Sleep Quality Predicts Worsening SLE Disease Activity
Background/Purpose: Poor sleep quality is commonly observed in patients with SLE. We hypothesize that poor sleep contributes to worsening SLE. The aims of this study…Abstract Number: 1673 • 2018 ACR/ARHP Annual Meeting
Validation and Evaluation of the Spanish Version of the Systemic LUPUS Activity Questionnaire in an Argentine Population
Background/Purpose: disease activity in Systemic Lupus Erythematosus (SLE) leads to damage, comorbidities and increased overall mortality. Frequent assessment is needed to adapt patients’ management. The…Abstract Number: 1674 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker Validation in a Large European Spanish Lupus Registry Cohort
Background/Purpose: Lupus Impact Tracker (LIT) is a ten item unidimensional patient reported outcome tool developed from and for patients with systemic lupus erythematosus (SLE). It…Abstract Number: 1675 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
Background/Purpose: Remission & Low Disease activity state (LDAS) are the two new health outcome measures developed with “treat to target” strategy in mind for Systemic…Abstract Number: 1676 • 2018 ACR/ARHP Annual Meeting
Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease affecting the physical, social, and psychological well-being of patients. Health related quality of life (HRQoL) measures…Abstract Number: 1677 • 2018 ACR/ARHP Annual Meeting
Evaluation of Erythrocyte Sedimentation Rate As a Marker of Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: SLEDAI is a global disease activity index for SLE and includes anti-DNA and complement levels. However, elevated anti-DNA or low C3 & C4 levels…Abstract Number: 1678 • 2018 ACR/ARHP Annual Meeting
How Consistently Do Publications Define SLE? a Systematic Review
Background/Purpose: Systemic lupus erythematosus (SLE) is clinically heterogeneous. ACR and/or SLICC classification criteria provide homogeneous populations for research purposes, but studies differ in selection and…Abstract Number: 1679 • 2018 ACR/ARHP Annual Meeting
Usefulness of Cardiac Screening in Patients with Systemic Lupus Erythematosus and Anti-Ro Positive Antibodies
Background/Purpose: Cardiac block in neonatal lupus is associated with placental transfer of anti-Ro antibodies. The effect of these antibodies on cardiac conduction disorders in adult…Abstract Number: 1680 • 2018 ACR/ARHP Annual Meeting
Serum Calprotectin in Systemic Lupus Erythematosus: Is It a Good Activity Biomarker?
Background/Purpose: Clinical manifestations of systemic lupus erythematosus (SLE) and infections sometimes are difficult to distinguish. In clinical practice low complement and anti(ds)DNA levels are used…Abstract Number: 1681 • 2018 ACR/ARHP Annual Meeting
Performance of the Proposed American College of Rheumatology / European League Against Rheumatism 2017 Classification Criteria for SLE in Adult and Juvenile Systemic Lupus Erythematosus and Other Anti-Nuclear Antibody Related Rheumatic Diseases
Background/Purpose: A new classification criteria for SLE was proposed at the ACR/ARHP 2017 annual meet. The aim of this study was to compare the performance…Abstract Number: 1682 • 2018 ACR/ARHP Annual Meeting
Correlation between SLE Specific and Generic Health Related Quality of Life Surveys, and Their Association with Patient Global Rating of Change and Lupus Low Disease Activity State: A Longitudinal Study
Background/Purpose: To determine the correlation between SLE-specific and generic patient reported outcomes measures (PROs), and to examine their associations with patients’ global rating of change…Abstract Number: 1683 • 2018 ACR/ARHP Annual Meeting
Variation in HEp-2 Antinuclear Antibody (ANA) Titer Is Strongly Associated with the ANA Kit Manufacturer
Background/Purpose: Titers of HEp-2 ANAs vary between laboratories, with many contributing factors. We sought to systematically determine the contribution of different ANA kit manufacturers to…Abstract Number: 1684 • 2018 ACR/ARHP Annual Meeting
Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality
Background/Purpose: Achieving remission and low lupus disease activity state (LDAS) in systemic lupus erythematosus (SLE) patients improves their prognosis in terms of damage accrual. But,…Abstract Number: 1685 • 2018 ACR/ARHP Annual Meeting
IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by deregulation of cytokine production. IL2 is an anti-inflammatory cytokine in SLE, but its loss…
ACR Meeting Abstracts